ANI Pharmaceuticals Supports Sarcoidosis Awareness Month

Author:

ANI Pharmaceuticals, Inc. (ANI) is proud to announce its support for Sarcoidosis Awareness Month, in partnership with the Foundation for Sarcoidosis Research (FSR). Sarcoidosis is a rare inflammatory disease characterized by the formation of granulomas in the lungs and other organs. Despite limited treatment options and no known cure, ANI and FSR are working together to increase disease awareness and provide support to patients.

During the month of April, ANI employees will be wearing “Say Sarcoidosis” pins as part of FSR’s National Awareness Campaign. Furthermore, on April 13th, ANI members will wear purple in honor of World Sarcoidosis Awareness Day. The campaign aims to raise awareness about sarcoidosis and its impact on individuals and communities.

In addition to their support for awareness initiatives, ANI acknowledges FSR’s Ignore No More campaign, which focuses on addressing the underrepresentation of Black Americans in clinical trials and improving the care for Black sarcoidosis patients. ANI encourages more education on sarcoidosis and its effects on this population.

Nikhil Lalwani, President and CEO of ANI Pharmaceuticals, expressed the company’s commitment to the sarcoidosis community. ANI is honored to partner with FSR as a Corporate Advisory Committee member to elevate the voices of those impacted by sarcoidosis and contribute to increasing awareness and education.

Mary McGowan, CEO of the FSR, expressed gratitude for ANI Pharmaceuticals’ dedication to increasing awareness and education about sarcoidosis. Both organizations will continue to collaborate throughout the year to support individuals living with sarcoidosis.

For more information about sarcoidosis and how to get involved, visit the FSR website.

ANI Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing, manufacturing, and marketing high-quality branded and generic prescription pharmaceutical products. Their commitment to delivering sustainable growth includes scaling up their Rare Disease business, enhancing research and development capabilities in Generics, and leveraging their U.S. manufacturing footprint.

Disclaimer: This press release may contain forward-looking statements that involve uncertainties and risks, as described in ANI’s filings with the Securities and Exchange Commission (“SEC”). These statements are not historical and may differ from actual results.

ANI Pharmaceuticals, Inc. operates in the biopharmaceutical industry, focusing on the development, manufacturing, and marketing of high-quality branded and generic prescription pharmaceutical products. With a commitment to delivering sustainable growth, ANI is dedicated to scaling up their Rare Disease business, enhancing research and development capabilities in Generics, and leveraging their U.S. manufacturing footprint.

The pharmaceutical industry is a critical sector that plays a vital role in providing healthcare solutions to individuals worldwide. It encompasses various companies engaged in the discovery, development, production, and marketing of drugs for therapeutic purposes. The industry is highly regulated to ensure the safety and efficacy of medications, with strict standards for research, manufacturing, and distribution.

Market forecasts for the pharmaceutical industry indicate steady growth in the coming years. Factors such as increasing healthcare expenditure, population aging, advancements in medical technology, and the prevalence of chronic diseases contribute to the industry’s positive outlook. According to Market Research Future, the global pharmaceutical market is expected to reach a value of $1.5 trillion by 2023.

However, the industry also faces challenges and issues. Drug pricing and affordability remain significant concerns, as the cost of medications can put a strain on healthcare systems and patients. Additionally, stringent regulations, patent expirations, and the increasing cost of research and development pose challenges for pharmaceutical companies.

It is essential for pharmaceutical companies like ANI Pharmaceuticals, Inc. to actively engage in disease awareness initiatives and advocacy efforts. Collaborations with organizations like the Foundation for Sarcoidosis Research (FSR) help raise awareness about rare diseases such as sarcoidosis and provide support to patients.

To learn more about ANI Pharmaceuticals, Inc. and their involvement in sarcoidosis awareness, you can visit their main website directly at ANI Pharmaceuticals. For additional information about sarcoidosis and how to get involved, you can visit the FSR website at Foundation for Sarcoidosis Research.